Biogen’s high-stakes Alzheimer’s gamble is being roasted by the experts. Is the amyloid beta theory dead?

Biogen $BIIB and its partners at Eisai had hoped to breathe some new life into the increasingly wobbly amyloid beta theory for theory for Alzheimer’s when they sounded an upbeat note about their latest data cut on BAN2401.